Literature DB >> 1722550

Basis for natural resistance to methotrexate in human acute non-lymphocytic leukemia.

J T Lin1, W P Tong, T M Trippett, D Niedzwiecki, Y Tao, C Tan, P Steinherz, B I Schweitzer, J R Bertino.   

Abstract

The basis of intrinsic resistance of blasts from patients with acute non-lymphocytic leukemia (ANLL) to methotrexate was studied. MTX polyglutamate formation was measured in blast cells from 19 patients with ANLL and in 7 pediatric patients with acute lymphocytic leukemia (ALL), after in vitro incubation for 24 h with 3H-methotrexate. There was no significant differences seen in the total amount of MTX plus polyglutamates measured between ANLL and ALL blasts, indicating that transport defects do not account for intrinsic MTX resistance in ANLL. However, there were significant differences between the amounts of long chain MTX polyglutamates found in ANLL cells as compared to ALL cells. Most, but not all, ANLL blasts were unable to form long chain polyglutamates. In as much as the level of MTX polyglutamates found in blast cells after MTX administration allows for retention of this drug, this property may explain, at least in part, the refractoriness of most patients with ANLL to methotrexate.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1722550     DOI: 10.1016/0145-2126(91)90189-z

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  8 in total

Review 1.  Molecular pharmacodynamics in childhood leukemia.

Authors:  R Pieters; M L den Boer
Journal:  Int J Hematol       Date:  2003-12       Impact factor: 2.490

2.  Phase II trial of oral aminopterin for adults and children with refractory acute leukemia.

Authors:  Peter D Cole; Richard A Drachtman; Angela K Smith; Sarah Cate; Richard A Larson; Douglas S Hawkins; John Holcenberg; Kara Kelly; Barton A Kamen
Journal:  Clin Cancer Res       Date:  2005-11-15       Impact factor: 12.531

Review 3.  Revitalizing antifolates through understanding mechanisms that govern susceptibility and resistance.

Authors:  Shannon Lynn Kordus; Anthony David Baughn
Journal:  Medchemcomm       Date:  2019-05-08       Impact factor: 3.597

4.  Cellular pharmacokinetics of ZD1694 in cultured human leukaemia cells sensitive, or made resistant, to this drug.

Authors:  Y Takemura; W Gibson; R Kimbell; H Kobayashi; H Miyachi; A L Jackman
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

Review 5.  Folate metabolism: a re-emerging therapeutic target in haematological cancers.

Authors:  Martha M Zarou; Alexei Vazquez; G Vignir Helgason
Journal:  Leukemia       Date:  2021-03-11       Impact factor: 11.528

6.  Biological activity and intracellular metabolism of ZD1694 in human leukemia cell lines with different resistance mechanisms to antifolate drugs.

Authors:  Y Takemura; H Kobayashi; H Miyachi; W Gibson; R Kimbell; A L Jackman
Journal:  Jpn J Cancer Res       Date:  1996-07

7.  LncRNA KCNQ1OT1 enhanced the methotrexate resistance of colorectal cancer cells by regulating miR-760/PPP1R1B via the cAMP signalling pathway.

Authors:  Di Xian; Yu Zhao
Journal:  J Cell Mol Med       Date:  2019-04-17       Impact factor: 5.310

8.  Binding of a Smad4/Ets-1 complex to a novel intragenic regulatory element in exon12 of FPGS underlies decreased gene expression and antifolate resistance in leukemia.

Authors:  Shachar Raz; Michal Stark; Yehuda G Assaraf
Journal:  Oncotarget       Date:  2014-10-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.